HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond.

Abstract
In the last few years, plants have become an increasingly attractive platform for recombinant protein production. This builds on two decades of research, starting with transgenic approaches to develop oral vaccines in which antigens or therapeutics can be delivered in processed plant biomass, and progressing to transient expression approaches whereby high yields of purified targets are administered parenterally. The advantages of plant-based expression systems include high scalability, low upstream costs, biocontainment, lack of human or animal pathogens, and ability to produce target proteins with desired structures and biological functions. Using transgenic and transient expression in whole plants or plant cell culture, a variety of recombinant subunit vaccine candidates, therapeutic proteins, including monoclonal antibodies, and dietary proteins have been produced. Some of these products have been tested in early phase clinical trials, and show safety and efficacy. Among those are mucosal vaccines for diarrheal diseases, hepatitis B and rabies; injectable vaccines for non-Hodgkin's lymphoma, H1N1 and H5N1 strains of influenza A virus, and Newcastle disease in poultry; and topical antibodies for the treatment of dental caries and HIV. As lead plant-based products have entered clinical trials, there has been increased emphasis on manufacturing under current Good Manufacturing Practice (cGMP) guidelines, and the preparation and presentation to the relevant government agencies of regulatory packages.
AuthorsVidadi Yusibov, Stephen J Streatfield, Natasha Kushnir
JournalHuman vaccines (Hum Vaccin) Vol. 7 Issue 3 Pg. 313-21 (Mar 2011) ISSN: 1554-8619 [Electronic] United States
PMID21346417 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies
  • Antibodies, Monoclonal
  • Cancer Vaccines
  • Escherichia coli Vaccines
  • Hepatitis B Vaccines
  • Influenza Vaccines
  • Rabies Vaccines
  • Vaccines
  • Vaccines, Synthetic
  • Viral Vaccines
  • Glucosylceramidase
Topics
  • Antibodies (immunology)
  • Antibodies, Monoclonal (immunology)
  • Cancer Vaccines (biosynthesis)
  • Clinical Trials as Topic
  • Enterotoxigenic Escherichia coli (immunology)
  • Escherichia coli Vaccines (biosynthesis)
  • Gaucher Disease (drug therapy)
  • Glucosylceramidase (immunology, therapeutic use)
  • Hepatitis B Vaccines (biosynthesis)
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype (immunology)
  • Influenza Vaccines (biosynthesis)
  • Lymphoma, Non-Hodgkin (immunology)
  • Newcastle disease virus (immunology)
  • Norwalk virus (immunology)
  • Plants (immunology)
  • Plants, Genetically Modified (immunology)
  • Rabies Vaccines (biosynthesis, immunology)
  • Vaccines (immunology)
  • Vaccines, Synthetic (immunology)
  • Viral Vaccines (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: